254 related articles for article (PubMed ID: 31207943)
1. The Peptide ERα17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells.
Lappano R; Mallet C; Rizzuti B; Grande F; Galli GR; Byrne C; Broutin I; Boudieu L; Eschalier A; Jacquot Y; Maggiolini M
Cells; 2019 Jun; 8(6):. PubMed ID: 31207943
[TBL] [Abstract][Full Text] [Related]
2. The Antitumor Peptide ERα17p Exerts Anti-Hyperalgesic and Anti-Inflammatory Actions Through GPER in Mice.
Mallet C; Boudieu L; Lamoine S; Coudert C; Jacquot Y; Eschalier A
Front Endocrinol (Lausanne); 2021; 12():578250. PubMed ID: 33815268
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the Anti-Proliferative GPER Inverse Agonist ERα17p with the Breast Cancer Cell Plasma Membrane: From Biophysics to Biology.
Trichet M; Lappano R; Belnou M; Salazar Vazquez LS; Alves I; Ravault D; Sagan S; Khemtemourian L; Maggiolini M; Jacquot Y
Cells; 2020 Feb; 9(2):. PubMed ID: 32075246
[TBL] [Abstract][Full Text] [Related]
4. Promising Perspectives of the Antiproliferative GPER Inverse Agonist ERα17p in Breast Cancer.
Kampa M; Lappano R; Grande F; Rizzuti B; Maggiolini M; Castanas E; Jacquot Y
Cells; 2023 Feb; 12(4):. PubMed ID: 36831322
[TBL] [Abstract][Full Text] [Related]
5. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).
Cirillo F; Lappano R; Bruno L; Rizzuti B; Grande F; Guzzi R; Briguori S; Miglietta AM; Nakajima M; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Aug; 38(1):335. PubMed ID: 31370872
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human estrogen receptor α tetrapeptidic fragment with dual antiproliferative and anti-nociceptive action.
Jouffre B; Acramel A; Belnou M; Santolla MF; Talia M; Lappano R; Nemati F; Decaudin D; Khemtemourian L; Liu WQ; Maggiolini M; Eschalier A; Mallet C; Jacquot Y
Sci Rep; 2023 Jan; 13(1):1326. PubMed ID: 36693877
[TBL] [Abstract][Full Text] [Related]
7. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
8. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
9. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
10. Arsenite and Cadmium Activate MAPK/ERK via Membrane Estrogen Receptors and G-Protein Coupled Estrogen Receptor Signaling in Human Lung Adenocarcinoma Cells.
Huff MO; Todd SL; Smith AL; Elpers JT; Smith AP; Murphy RD; Bleser-Shartzer AS; Hoerter JE; Radde BN; Klinge CM
Toxicol Sci; 2016 Jul; 152(1):62-71. PubMed ID: 27071941
[TBL] [Abstract][Full Text] [Related]
11. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling.
Santolla MF; De Francesco EM; Lappano R; Rosano C; Abonante S; Maggiolini M
Cell Signal; 2014 Jul; 26(7):1466-75. PubMed ID: 24662263
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA Inhibits Triple-Negative Breast Cancer Cells MDA-MB-231 via G Protein-Coupled Estrogen Receptor- (GPER-) Dependent Signaling Pathway.
He Y; Yang K; Liu J; Shi D; Zhang Z; Yang J; Chen M; Zhao P
Dis Markers; 2023; 2023():8371623. PubMed ID: 36741908
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
14. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
16. Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells.
Chimento A; Casaburi I; Rosano C; Avena P; De Luca A; Campana C; Martire E; Santolla MF; Maggiolini M; Pezzi V; Sirianni R
Mol Nutr Food Res; 2014 Mar; 58(3):478-89. PubMed ID: 24019118
[TBL] [Abstract][Full Text] [Related]
17. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.
Scaling AL; Prossnitz ER; Hathaway HJ
Horm Cancer; 2014 Jun; 5(3):146-160. PubMed ID: 24718936
[TBL] [Abstract][Full Text] [Related]
18. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
[TBL] [Abstract][Full Text] [Related]
19. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer.
Santolla MF; Avino S; Pellegrino M; De Francesco EM; De Marco P; Lappano R; Vivacqua A; Cirillo F; Rigiracciolo DC; Scarpelli A; Abonante S; Maggiolini M
Cell Death Dis; 2015 Jul; 6(7):e1834. PubMed ID: 26225773
[TBL] [Abstract][Full Text] [Related]
20. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells.
Lappano R; Rosano C; Santolla MF; Pupo M; De Francesco EM; De Marco P; Ponassi M; Spallarossa A; Ranise A; Maggiolini M
Curr Cancer Drug Targets; 2012 Jun; 12(5):531-42. PubMed ID: 22414008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
